NVP 2

Target: This ligand targets cyclin-dependent kinase 9 (CDK9) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for cyclin-dependent kinase 9 (CDK9). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings cyclin-dependent kinase 9 (CDK9) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Design for NVP 2: NVP 2 can be used as a binding ligand to construct PROTACs that recruit an E3 ubiquitin ligase and drive ubiquitination of the target protein. This enables systematic evaluation of ternary complex formation, degradation potency, and selectivity across linker lengths and attachment sites to optimize targeted protein loss.

• Targeted Degradation Pathway Mapping: Incorporate NVP 2 into PROTAC formats to investigate the degradation mechanism of the recruited target, including dependence on proteasome activity and ubiquitin conjugation. By comparing degradation kinetics and dose–response relationships, researchers can map pathway requirements and identify conditions that maximize efficient removal rather than mere inhibition.

• Structure–Activity Optimization: Use NVP 2-based PROTACs to perform structure–activity relationship studies by varying linker composition, rigidity, and length, as well as ligand positioning. These experiments help correlate molecular geometry with ternary complex stability and degradation efficiency, guiding rational optimization toward stronger target engagement and improved degradation selectivity.

• Comparative Degrader Profiling: Employ NVP 2 PROTAC constructs to benchmark degradation performance against alternative ligands or E3-recruiting modules. Side-by-side profiling of multiple PROTAC variants can reveal how NVP 2 contributes to potency, degradation selectivity, and resistance to cellular feedback, supporting selection of the most informative degrader tool compounds for mechanistic studies.

NVP 2 is a CDK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of NVP 2 is characterized by primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.